argenx SE commenced a tender offer for Forte Biosciences on January 14, offering $1.62 per share for the Torrey Pines biotechnology company with 96.3 million diluted shares outstanding. The all-cash bid values Forte at approximately $156 million, representing a 27% premium to the January 13 close of $1.27. argenx expects to complete the acquisition by late February, subject to minimum tender and HSR clearance.
Forte Biosciences repositioned itself in 2023 after discontinuing FB-401, an IL-12/23 inhibitor for inflammatory bowel disease that failed Phase 2b endpoints in ulcerative colitis. The company returned $46 million to shareholders via special dividend in April 2024 and refocused on FB-102, a topical phosphodiesterase-4 inhibitor targeting congenital ichthyoses, a family of rare genetic skin disorders affecting approximately 16,000 patients in the United States. Forte's cash position stood at $37.2 million as of September 30, 2024, with a quarterly burn rate near $3.8 million. The tender premium compensates for execution risk while giving argenx immediate access to a late-preclinical dermatology asset without competitive auction dynamics.
The acquisition extends argenx's immunology franchise beyond its $9.7 billion annual run-rate drug Vyvgart, an FcRn blocker approved for myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Dermatology represents a natural adjacency: autoimmune blistering diseases like pemphigus vulgaris share pathophysiology with neuromuscular indications, and argenx already has clinical infrastructure in academic dermatology centers. FB-102's topical formulation addresses a different mechanism—PDE-4 inhibition reduces inflammatory cytokines locally—but targets a patient population argenx can reach through existing rare-disease distribution. The deal also removes $156 million in potential future capital competition for specialized dermatology clinical trial sites and key opinion leaders, a resource constraint that matters more than the absolute dollar outlay for a company with $2.1 billion in cash and marketable securities.
Allocators should track three developments. First, the tender minimum: argenx set the bar at a majority of fully diluted shares, meaning retail holders of Forte's thinly traded stock have material influence over closing by early February. Second, Vyvgart's Q1 2025 sales print in late April will indicate whether argenx's platform thesis justifies diversification or whether management is prematurely allocating capital outside the core FcRn franchise. Third, any disclosure on FB-102's development timeline—argenx has not committed to Phase 1 initiation—will clarify whether this is an earnest pipeline build or an opportunistic tuck-in for tax-loss harvesting and dermatology network access.
The deal prices Forte at 4.2x trailing cash after dividend recapitalization, a valuation that reflects asset risk but also scarcity value in dermatology platforms with no debt and clean IP. argenx's last acquisition, a $1.3 billion purchase of Zai Lab's global Vyvgart rights in 2022, was a revenue-generating asset with established proof-of-concept. This one is earlier, smaller, and cheaper per dollar of balance sheet acquired.